ReviewFrontiers in nutrition2025
Intermittent fasting in the treatment of type 2 diabetes.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Intermittent fasting in diabetic retinopathy: microbiome modulation, mechanisms, and clinical insights.Cardiovascular endocrinology & metabolism · 2026Review
- Sex-Specific Responses to Intermittent Fasting: A Narrative Review Across Physiological, Clinical, and Psychosocial Contexts.Nutrients · 2026Review
- [Nutrition recommendations for people with diabetes (Update 2026)].Wiener klinische Wochenschrift · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of type 2 diabetes mellitus (T2DM) has inspired researchers to investigate therapies and tools supporting the treatment of this disease. One such tool is intermittent fasting (IF). Given the nature and mechanism of action of IF, it would be logical for it to have a beneficial effect on T2DM patients. This study analyzes the role of IF in the treatment of type 2 diabetes, used alongside standard recommendations, based on the current literature available to the authors. The authors discuss the benefits of IF in T2DM treatment, such as improved glycaemic control, improved insulin sensitivity, facilitated adherence to recommendations, weight reduction, and lower risk of complications. This study covers the results of meta-analyses, systematic reviews, and randomized controlled trials (RCTs) and shows how novel technologies, including continuous glucose monitors and mobile applications, can support the implementation of IF. The importance of safety monitoring is also highlighted, particularly in insulin-treated patients due to the potential risk of hypoglycaemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.